Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856978 | 0.86 | EPHX2 (0.44) | LRRK2TGFBR1CCNT1CCNA2CDK2 | |
| SCHEMBL857828 | 0.84 | LRRK2 (0.45) | LRRK2TGFBR1CCNT1CCNA2CDK2 | |
| SCHEMBL857757 | 0.84 | MEN1 (0.43) | TGFBR1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL15061525 | 0.83 | LRRK2 (0.47) | LRRK2CDK2IDO1GRM5KDR | |
| SCHEMBL857304 | 0.82 | TGFBR1 (0.47) | LRRK2TGFBR1CCNT1CCNA2CDK2 | |
| SCHEMBL857747 | 0.80 | TGFBR1 (0.41) | LRRK2TGFBR1CCNT1CCNA2CDK2 | |
| SCHEMBL857303 | 0.77 | LRRK2 (0.45) | LRRK2CDK2IDO1PDGFRAKDR | |
| SCHEMBL857019 | 0.74 | LRRK2 (0.46) | LRRK2DYRK1AKMT2A | |
| SCHEMBL857088 | 0.74 | LRRK2 (0.55) | LRRK2TGFBR1CCNT1CCNA2CDK2 | |
| SCHEMBL858066 | 0.73 | LRRK2 (0.57) | LRRK2TGFBR1CDK2IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LRRK2 491/4885TGFBR1 4446/4885CCNT1 1376/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LRRK2 491/4885TGFBR1 4446/4885CCNT1 1376/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LRRK2 491/4885TGFBR1 4446/4885CCNT1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.